The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets

By Raga Krishnakumar, W. Kraus. Molecules and Cells, 2010

868 citations recorded by the source corpus.

Summary The abundant nuclear enzyme PARP-1, a multifunctional regulator of chromatin structure, transcription, and genomic integrity, plays key roles in a wide variety of processes in the nucleus. Recent studies have begun to connect the molecular functions of PARP-1 to specific physiological and pathological outcomes, many of which can be altered by an expanding array of chemical inhibitors of PARP enzymatic activity.

Subfields: Molecular Biology, Oncology, Plant Science

View Paper: https://www.semanticscholar.org/paper/1f91f083b116ee3b6354dc893fb1a06bb2fa2163

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. C. Lord
2. Alan Ashworth
3. W. Kraus
4. Nektarios Tavernarakis
5. Mark J. O'Connor

In Oncology

1. C. Lord
2. Alan Ashworth
3. Rebecca Gupte
4. Ziying Liu
5. W. Kraus
6. Mark J. O'Connor

In Plant Science

1. W. Kraus

Citations in the corpus

• PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation (2011, neutral): “It will be interesting to explore whether PARylation can directly modulate the activity of key metabolic transcriptional regulators, as PARP-1 may contribute to nuclear processes other than DNA repair (Krishnakumar and Kraus, 2010).”
• DNA damage and its links to neurodegeneration (2014, neutral): “A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript proteins, and a C-terminal catalytic domain that binds NAD+ and transfers ADP-ribose from NAD+ to acceptor sites on proteins (Krishnakumar and Kraus, 2010).”
• Crosstalk between apoptosis, necrosis and autophagy. (2013, background): “As already mentioned earlier, PARP1 belongs to a family of nuclear enzymes, modulating DNA repair, transcriptional regulation, chromatin modification and genomic stability through polyADP-ribosylation [131,132].”
• PARP Inhibitors: The First Synthetic Lethal Targeted Therapy (2017, background): “It is important to note that PARP1 and PARP2 have multiple important roles beyond the DDR such as transcription, apoptosis and immune function; the anti-tumor efficacy of PARPi might also reflect alterations in these functions (3).”
• PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes (2017, background): “PARylation of KDM5B, a histone lysine demethylase that acts on histone H3 Lys4 trimethyl (H3K4me3), by PARP-1 inhibits the binding of KDM5B to chromatin and its demethylase activity at specific sites across the genome (Krishnakumar and Kraus 2010b).”